Michael Hanley
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael Hanley
Spyre Therapeutics, Inc. reported in an 8-K filed April 12, 2023 that Michael Hanley resigned as Chief Business Officer, effective April 14, 2023. Spyre Therapeutics, Inc. reported in an 8-K filed August 25, 2022 that Michael Hanley was appointed Chief Business Officer, effective August 23, 2022.
“Michael Hanley, the Company's Chief Business Officer, and Linda Neuman, the Company's Chief Medical Officer, will be departing from the Company, effective April 14, 2023.”
“On August 23, 2022, the Board appointed Michael Hanley to the position of the Company’s Chief Business Officer (“CBO”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Spyre Therapeutics, Inc. (SYRE)
Proxy statement
2022-08-23–2023-04-17
Last confirmed by a filing; no departure on record
-
Spyre Therapeutics, Inc. (SYRE)
Proxy statement
Start not stated–2023-04-14
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.